The role of the ERN EpiCARE Research Council is to support research conducted by EpiCARE members, with an aim to improve the quality and quantity of research within the network.
Specific goals include:
The EpiCARE Research Council includes EpiCARE’s Coordinator, 4 members of the EpiCARE Steering comittee, the ECET Chair, the Registry representative, the ePAG representatives, a representative of a current joint ERN/European research Initiatives (eg EJP RD, Human Brain Project that provide ressources to the network), the EpiCARE Research projects manager, the EpiCARE data manager and an ILAE representative.
The chair of EpiCARE’s Research Council is Helen Cross, deputy chair is Kees Braun. Members are Alexis Arzimanoglou, Sandor Beniczky, Ingmar Blümcke, Philippe Ryvlin, Renzo Guerrini, Rainer Surges, Eugen Trinka, Lieven Lagae, Rima Nabbout and Emilio Perucca.
An EpiCARE project will be defined as a project that is led by a number of EpiCARE members (at least 2) or from a single centre where data for a study is gathered from other EpiCARE HCP.
The project must be proposed to the research council prior to any funding application, and have undergone a quality check/peer review.
In order for ERN EpiCARE support to be given to a project, a project should be reviewed by the council. On submission, a reviewer will be nominated from the network and advice provided within 2 weeks. A letter will be provided by the Council Chair
Budget: €131 360 126 (Grants of up to EUR 2.5million)
Deadline model: multiple cut-off
Is intended to meet the following specific objectives:
The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation. The endpoint in the project should be a completely functional version of the technology suitable for clinical validation, supported by a sound and implementable commercialisation/exploitation strategy.
Proposals are expected to contribute to at least one of the following outcomes:
Budget: €427 276 125 (Per project: 36 months)
Deadline model: single-stage
Deadline: 15 November 2022 17:00:00 Brussels time
Scope: The Doctoral Networks aim to train a new generation of creative entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.
For supported doctoral candidates
For participating organizations:
Deadline date: December 31, 2022
Budget: €2 000
The Dravet Syndrome Foundation Spain (FSD) Open-Access Support Program is an ongoing call for proposals, and it joins recent research initiatives initiated by FSD, such as the Call for Innovative Research Projects in Advanced Therapies for Dravet Syndrome or the Program for the development of new scientific tools initiated last February 1st together with Tel Aviv University.
This is an ongoing call only limited by FSD’s budget. Authors can apply for a grant of up to EUR 2,000 (approximately $2400 USD) to cover the open-access publishing fees required for the publication in international scientific journals of a manuscript resulting from high quality research on Dravet syndrome.
The Innovative Health Initiative (IHI), a European Union public-private partnership funding health research and innovation, has published draft information on upcoming funding opportunities in 2022 in order to give potential applicants additional time to find or build a consortium and prepare a strong proposal.
The first call for proposals will be launched in the first half of 2022. The following draft themes could be included in the future calls:
Single stage calls
Two stage calls
Please check the IHI website and social media for regular updates related to the upcoming calls.
Funding for scientific meetings or workshops relevant to neurobiology of epilepsy can also be provided through the NBC. Requests for sponsoring such workshops are considered for funding on an annual basis by the NBC. To apply, please complete the NBC Funding Request Form by 31 July of the year preceding the planned meeting. Decisions on support will be announced by the end of March of the year of the event.
Aims: The first aim of the Networking Support Scheme in the European Joint Programme on Rare Diseases (EJP RD) is to encourage sharing of knowledge on rare diseases or rare cancers between health care professionals, researchers and patients in new or expanding research networks by funding networking events.
The second aim of the Networking Support Scheme is to enable or increase the participation of usually underrepresented countries in Europe in new and in expanding research networks on rare diseases or rare cancers.
Budget: In this Networking Support Scheme applicants can apply for a budget of a maximum of 30,000 € per event.
Focus of the Networking events: The scheme will provide financial support to applicants to organize workshops or conferences. These workshops or conferences are meant to:
The focus of these workshops or conferences should be (the implications of) research results and innovative solutions. The results of these networking events may lead to future collaborative and novel research efforts.
Requirements: at least one Principal applicant and two co-applicants from three different countries mentioned above have to apply together for support of a Networking event.
Dates: the Call for the NSS is open on a continuous basis. Events may be organized between 6 and 18 months after the application date for 2021. From 2022 onwards, events may be organized between 6 and 12 months after the application date.
The next applications will be collected on December 2, 2021 at 14.00 (CET)
The applications will be collected on the following preliminary dates in 2022.
March 1, 2022 at 14.00 (CEST)
September 1, 2022 at 14.00 (CEST)
December 1, 2022 at 14.00 (CET).
The Global Innovation Fund (GIF) is currently inviting applications for its Grants program to support breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
Deadline – Ongoing
The Global Innovation Fund invests in the development, rigorous testing, and scaling up of new products, services, business process, or policy reforms. Through its grants, GIF supports these breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
If you are a non-profit and your innovation does not involve generating revenues from users or customers, a grant is likely to be most appropriate.
Stages of Funding
GIF has a staged funding approach, whereby the amount of funding available is tiered according to the level of maturity of your innovation and the activities proposed. The three tiers are:
Pilot – the innovation is at an early stage but you have a credible plan for how it can be developed and tested in a real-world setting. Funding of up to USD 230,000 is available to test core assumptions around operational, social, and financial viability.
Test and transition – the innovation has already shown promise of success at a small scale, and you have some information on your operational, social, and financial viability which you want to solidify before you scale. Funding of up to USD 2.3 million is available to support further growth and generate additional evidence on whether the innovation can achieve social impact and market viability, for commercial innovations.
Scale – the innovation has a strong evidence base and logistically credible plan for scaling to reach millions of people. Funding of up to USD 15 million is available to expand the reach of innovations with a view to reaching millions of people in the long term if successful.
What they Fund?
At GIF, they believe that innovation, by which they mean any solution that has potential to address an important development problem more effectively than existing approaches, can come from anyone, anywhere.
This means that they accept applications working in any sector in any developing country.
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs, or researchers apply through an affiliated organisation.
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs or researchers apply through an affiliated organisation.
GIF is open to innovations which meet their criteria in any sector or country. However, there are some activities they do not fund. These include:
Application for 2023 is open from August 01 – October 31, 2022
The objective of the “Clinical Fellowship Programme” is to provide a well- defined clinical observational experience in a department with recognised expertise in a specific field.
With this programme, neurologists that are still in the process of training, or recently qualified and setting up a new service/practice can learn from observing the usual practice in that new department, including any or all of clinical practice, service structures or specific techniques conducted in the Hosting Department.
The programme is designed for a minimum stay of 6 up to a maximum of 12 weeks in a Hosting Department outside the country of residence (with a minimum of frequency of 5 days/week in each weeks).
Starting from 2021, the number of granted weeks will be increased from 210 weeks (35x 6 weeks) to 300 weeks. The granted weeks per application are based on justification for the length of the stay and the grades of the 3 separate reviewers .
The grant for the programme will be 425,-€ per week, plus travelling costs (maximum of 300 Euro of travelling costs).
Travelling costs will only be reimbursed after the end of the clinical fellowship, upon receipt of report and confirmation from both the clinical fellow and mentor at Host Department, as well as the evaluation forms.
The fellow’s final report should include a summary of activity during the fellowship and the achieved knowledge/skills.
Ideally, the grantee has knowledge of the language at the host department, as not all patient-rounds can be held in English.
The world’s largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
Nominations for 2023 are open
The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research, and winners may be of any nationality and work in any country around the globe. This broad perspective is reflected in the diverse fields of previous Brain Prize winners.
The Prize may be awarded to one or more scientists who have distinguished themselves through outstanding contributions to any field of neuroscience, from fundamental studies to research related to understanding and treatment of diseases of the brain and other parts of the nervous system.
Deadline: 8th November 2022
Researchers based in EU/Switzerland are fully eligible to apply to a an ERC Synergy Grant, as part of a group of 2-4 PIs with complimentary expertise joining forces to tackle a complex research problem. Up to €10 mio of funding can be requested per project with the open call closing on 8 November.
Join us for the second edition of the EIC Summit which will take place on 7-8 December 2022 in Brussels. Do not miss the key European deep-tech innovation event of the year, bringing together start-ups, researchers, investors, policy makers and corporates.
You can sign up below to receive the EpiCARE Research Calls Newsletters, sent a few times a year, to inform about the new research calls: